Opportunistic mycosis
MONDO:0002312A mycosis that arises from infection in an immunologically compromised host.
Also known as: opportunistic systemic mycoses
149 clinical trials for this condition and its sub-types, 0 tagged with Opportunistic mycosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Opportunistic mycosis
-
Candidiasis 19 trials · 58 incl. sub-types
9 sub-types
- Cutaneous candidiasis 0 trials · 25 incl. sub-types Sub-types →
- Candidiasis, invasive 14 trials · 18 incl. sub-types Sub-types →
- Disseminated candidiasis 16 trials
- Oral candidiasis 4 trials
- Neonatal candidiasis 1 trial
- Candida glabrata infection 0 trials
- Candidal paronychia 0 trials
- Congenital candidiasis 0 trials
- Esophageal candidiasis 0 trials
-
Aspergillosis 20 trials · 56 incl. sub-types
4 sub-types
- Pulmonary aspergilloma 11 trials · 38 incl. sub-types Sub-types →
- Allergic bronchopulmonary aspergillosis 15 trials Sub-types →
- Neuroaspergillosis 1 trial
- Aspergillus niger infection 0 trials
-
Opportunistic systemic mycosis 0 trials · 23 incl. sub-types
3 sub-types
- Disseminated candidiasis 16 trials
- Penicilliosis 5 trials
- Trichosporonosis 0 trials · 2 incl. sub-types Sub-types →
-
Zygomycosis 19 trials
1 sub-type
- Basidiobolomycosis 0 trials Sub-types →
-
Pneumocystosis 19 trials
-
Cryptococcosis 5 trials · 10 incl. sub-types
1 sub-type
- Cryptococcal meningitis 7 trials
-
Fusariosis 4 trials
-
Hyalohyphomycosis 1 trial
-
Geotrichosis 0 trials
-
Maple bark strippers' lung 0 trials
-
Microsporidiosis 0 trials
1 sub-type
- Encephalitozoonosis 0 trials
-
Phaeohyphomycosis 0 trials
Most studied deeper sub-types
-
New pill could fight dangerous fungal infections
Disease control Stopped earlyThis study tested a new oral antifungal drug, ibrexafungerp, for treating serious Candida infections in the blood or internal organs. 68 adults received an IV antifungal followed by either ibrexafungerp or standard oral fluconazole. The trial was stopped early, so the results are…
Phase 3 • Sponsor: Scynexis, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Promising fungal infection treatment study halted early
Disease control Stopped earlyThis study tested whether adding an inhaled medication (PC945) to standard antifungal drugs could help people with a severe, hard-to-treat lung fungal infection called invasive pulmonary aspergillosis. The trial aimed to see if the combination improved survival and response by da…
Phase 3 • Sponsor: Pulmocide Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope against deadly molds? early trial cut short
Disease control Stopped earlyThis study tested a drug called fosmanogepix in 21 adults with invasive mold infections (like Aspergillus or rare molds) who had few other options. The trial was stopped early, so we have limited data on how well it works or its safety.
Phase 2 • Sponsor: Basilea Pharmaceutica • Aim: Disease control
Last updated Jun 26, 2026 17:54 UTC